(Q38096489)

28 August 2017

Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets (English)

1 reference

28 August 2017

0 references

1 reference

1 reference

Simon J Draper

2

0 references

author name string

Simone C de Cassan

series ordinal

1

1 reference

28 August 2017

1 April 2013

1 reference

Expert Review of Vaccines

28 August 2017

1 reference

28 August 2017

12

1 reference

28 August 2017

4

1 reference

28 August 2017

365-378

1 reference

28 August 2017

Vaccines against malaria

1 reference

Lessons learned from HIV-1 vaccine trials: new priorities and directions

21 January 2018

1 reference

Improved outlook on HIV-1 prevention and vaccine development

21 January 2018

1 reference

Adjuvants for human vaccines

21 January 2018

1 reference

Viruses as vaccine vectors for infectious diseases and cancer

21 January 2018

1 reference

Vaccine delivery methods using viral vectors

21 January 2018

1 reference

Immunologic basis of vaccine vectors

21 January 2018

1 reference

Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA

21 January 2018

1 reference

Cross-presentation by dendritic cells

21 January 2018

1 reference

Autophagy and the immune system

21 January 2018

1 reference

Innate immune recognition of viruses and viral vectors

21 January 2018

1 reference

Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome

21 January 2018

1 reference

Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity

21 January 2018

1 reference

Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity

21 January 2018

1 reference

Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors

21 January 2018

1 reference

Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection

21 January 2018

1 reference

A whole-genome association study of major determinants for host control of HIV-1

21 January 2018

1 reference

Common west African HLA antigens are associated with protection from severe malaria

21 January 2018

1 reference

The complexity of protective immunity against liver-stage malaria

21 January 2018

1 reference

Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites.

21 January 2018

1 reference

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

21 January 2018

1 reference

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector

21 January 2018

1 reference

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

21 January 2018

1 reference

Genetic immunization in the lung induces potent local and systemic immune responses

21 January 2018

1 reference

CD8+ T effector memory cells protect against liver-stage malaria

21 January 2018

1 reference

Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.

21 January 2018

1 reference

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

21 January 2018

1 reference

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

21 January 2018

1 reference

Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component

21 January 2018

1 reference

Malaria vaccines: focus on adenovirus based vectors.

21 January 2018

1 reference

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

21 January 2018

1 reference

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)

21 January 2018

1 reference

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

21 January 2018

1 reference

Prime-boost vectored malaria vaccines: progress and prospects

21 January 2018

1 reference

Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen

21 January 2018

1 reference

New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1

21 January 2018

1 reference

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity

21 January 2018

1 reference

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

21 January 2018

1 reference

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.

21 January 2018

1 reference

Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.

21 January 2018

1 reference

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species

21 January 2018

1 reference

Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.

21 January 2018

1 reference

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

21 January 2018

1 reference

The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus

21 January 2018

1 reference

Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements

21 January 2018

1 reference

Blood-stage malaria vaccines - recent progress and future challenges

21 January 2018

1 reference

Effective induction of high-titer antibodies by viral vector vaccines

21 January 2018

1 reference

Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei

21 January 2018

1 reference

Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.

21 January 2018

1 reference

Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria

21 January 2018

1 reference

Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection

21 January 2018

1 reference

Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth

21 January 2018

1 reference

ΔE1 and high-capacity adenoviral vectors expressing full-length codon-optimized merozoite surface protein 1 for vaccination against Plasmodium falciparum

21 January 2018

1 reference

Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay

21 January 2018

1 reference

Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1

21 January 2018

1 reference

Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.

21 January 2018

1 reference

A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity

21 January 2018

1 reference

Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus

21 January 2018

1 reference

The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody

21 January 2018

1 reference

Reticulocyte-binding protein homologue 5 - an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum.

21 January 2018

1 reference

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

21 January 2018

1 reference

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins

21 January 2018

1 reference

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

21 January 2018

1 reference

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

21 January 2018

1 reference

Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys

21 January 2018

1 reference

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine

21 January 2018

1 reference

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

21 January 2018

1 reference

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

21 January 2018

1 reference

Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial

21 January 2018

1 reference

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)

21 January 2018

1 reference

A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults

21 January 2018

1 reference

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors

21 January 2018

1 reference

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors

21 January 2018

1 reference

Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults

21 January 2018

1 reference

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults

21 January 2018

1 reference

Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria

21 January 2018

1 reference

A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals

21 January 2018

1 reference

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans

21 January 2018

1 reference

High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model

21 January 2018

1 reference

Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses

21 January 2018

1 reference

The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species

21 January 2018

1 reference

Kinetic constraints on the development of a malaria vaccine.

21 January 2018

1 reference

A field trial to assess a blood-stage malaria vaccine

21 January 2018

1 reference

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

21 January 2018

1 reference

Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice

21 January 2018

1 reference

Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A

21 January 2018

1 reference

T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein

21 January 2018

1 reference

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant

21 January 2018

1 reference

Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant

21 January 2018

1 reference

Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs

21 January 2018

1 reference

Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination

21 January 2018

1 reference

Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein.

21 January 2018

1 reference

Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.

21 January 2018

1 reference

Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1.

21 January 2018

1 reference

Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs

21 January 2018

1 reference

Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.

21 January 2018

1 reference

An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.

21 January 2018

1 reference

Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge

21 January 2018

1 reference

Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity.

21 January 2018

1 reference

Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol

21 January 2018

1 reference

The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert

21 January 2018

1 reference

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone

21 January 2018

1 reference

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.

21 January 2018

1 reference

Rabies vaccines: WHO position paper--recommendations.

21 January 2018

1 reference

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

21 January 2018

1 reference

Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen

21 January 2018

1 reference

Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.

21 January 2018

1 reference

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

21 January 2018

1 reference

Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus

21 January 2018

1 reference

Poxvirus-vectored vaccines for rabies--a review

21 January 2018

1 reference

Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

21 January 2018

1 reference

Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses

21 January 2018

1 reference

Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predict enhanced immunogenicity in vivo.

21 January 2018

1 reference

Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector.

21 January 2018

1 reference

Increased human immunodeficiency virus type 1 Env expression and antibody induction using an enhanced alphavirus vector

21 January 2018

1 reference

Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.

21 January 2018

1 reference

Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection

21 January 2018

1 reference

Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.

21 January 2018

1 reference

Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6

21 January 2018

1 reference

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

21 January 2018

1 reference

Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies

21 January 2018

1 reference

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

21 January 2018

1 reference

Targeting TLRs expands the antibody repertoire in response to a malaria vaccine.

21 January 2018

1 reference

Antibody repertoire: embracing diversity.

21 January 2018

1 reference

HIV vaccine design: the neutralizing antibody conundrum

21 January 2018

1 reference

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

21 January 2018

1 reference

The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection

21 January 2018

1 reference

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

21 January 2018

1 reference

B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study

21 January 2018

1 reference

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

21 January 2018

1 reference

Antibody-based protection against HIV infection by vectored immunoprophylaxis

21 January 2018

1 reference

Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex

21 January 2018

1 reference

Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction

21 January 2018

1 reference

Programming the magnitude and persistence of antibody responses with innate immunity

21 January 2018

1 reference

Cytokine-secreting follicular T cells shape the antibody repertoire

21 January 2018

1 reference

Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines

21 January 2018

1 reference

High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria

21 January 2018

1 reference

Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens

21 January 2018

1 reference

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

21 January 2018

1 reference

A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity

21 January 2018

1 reference

Biosensor-based characterization of serum antibodies during development of an anti-IgE immunotherapeutic against allergy and asthma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.13.11

1 reference

28 August 2017

1 reference

PubMed ID

23560918